Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda Reacquires Actos Rights in Canada | Contract Pharma

What are you searching for?

Sign in
Breaking News

Takeda Reacquires Actos Rights in Canada

Takeda Canada, Inc. has reacquired Canadian commercial rights to Actos, an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda licensed the drug to Lilly in 1999 as part of a worldwide agreement.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda Canada, Inc. has reacquired Canadian commercial rights to Actos, an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda licensed the drug to Lilly in 1999 as part of a worldwide agreement.

“Reacquiring the commercial rights to Actos is Takeda’s first opportunity to establish a commercial presence in Canada,” said Daaron Dohler, general manager at Takeda Canada. “It also underscores Takeda’s ongoing efforts to reinforce our global operations and build a stronger presence in North America.”

Actos was approved by Health Canada as monotherapy to decrease insulin resistance and blood glucose levels in patients with type 2 diabetes mellitus, in September 2000. Takeda took over responsibility for the drug in the Canadian market in mid-June, and currently sells it in other territories, including the U.S., Japan and most of Europe.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters